Evidence map›Paper›PMID 26727153›Full record

ReviewTrends in biotechnology2016

Overcoming Gene-Delivery Hurdles: Physiological Considerations for Nonviral Vectors.

Andrew B Hill, Mingfu Chen, Chih-Kuang Chen, Blaine A Pfeifer, Charles H Jones

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Trends in biotechnology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 54 papers.

0numbers the graph read from it
0cells of the map it votes in
54citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

54 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Nanotherapy for Neural Retinal Regeneration.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025
    Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Article
  11. Review
  12. Review
  13. Article
  14. Article
  15. Review
  16. Article
  17. Review
  18. Review
  19. Nanodelivery of nucleic acids.Nature reviews. Methods primers · 2022
    Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Andrew B HillAbcombi Biosciences Inc, Buffalo, NY, USA; McKetta Department of Chemical Engineering, The University of Texas at Austin, Austin, TX, USA.
Mingfu ChenDepartment of Chemical and Biological Engineering, University at Buffalo, The State University of New York, Buffalo, BY, USA.
Chih-Kuang ChenDepartment of Fiber and Composite Materials, Feng Chia University, Taichung, Taiwan, ROC.
Blaine A PfeiferAbcombi Biosciences Inc, Buffalo, NY, USA; Department of Chemical and Biological Engineering, University at Buffalo, The State University of New York, Buffalo, BY, USA. Electronic address: blainepf@buffalo.edu.
Charles H JonesAbcombi Biosciences Inc, Buffalo, NY, USA; Department of Chemical and Biological Engineering, University at Buffalo, The State University of New York, Buffalo, BY, USA. Electronic address: cjones9@buffalo.edu.

Funding

A Hybrid Bio-synthetic Vector Designed to Elicit Directed in vivo Immune ResponseR21AI117309 · NIAID · STATE UNIVERSITY OF NEW YORK AT BUFFALO · PI PFEIFER, BLAINE A. · 2016 to 2017
$435k
A Hybrid Biomaterial-biological Vector for Antigen Presenting Cell Gene DeliveryR03AI088485 · NIAID · TUFTS UNIVERSITY MEDFORD · PI PFEIFER, BLAINE A. · 2010 to 2011
$145k
NIAID NIH HHS R03 AI088485NIAID NIH HHS R21 AI117309
6 · The paper itself

Abstract

With the use of contemporary tools and techniques, it has become possible to more precisely tune the biochemical mechanisms associated with using nonviral vectors for gene delivery. Consequently, nonviral vectors can incorporate numerous vector compositions and types of genetic cargo to develop diverse genetic therapies. Despite these advantages, gene-delivery strategies using nonviral vectors have poorly translated into clinical success due to preclinical experimental design considerations that inadequately predict therapeutic efficacy. Furthermore, the manufacturing and distribution processes are critical considerations for clinical application that should be considered when developing therapeutic platforms. In this review, we evaluate potential avenues towards improving the transition of gene-delivery technologies from in vitro assessment to human clinical therapy.

Indexed as

Drug Delivery SystemsGenetic VectorsGenetic TherapyHumans

Identifiers

PMID26727153
PMCPMC5800990

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.